Navigation Links
BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/7/2009

NOVATO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14th, 2009 at 11:00 a.m. PT.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioM
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
10. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
11. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... March 28, 2015 With more ... the fields of osteoporosis, osteoarthritis and musculoskeletal diseases ... it may be the first time in the ... forum that the hot-button topic is an emerging ... the well-accepted scientific principles of Wolff’s law, osteogenic ...
(Date:3/28/2015)... 28, 2015 India Network visitor ... made available to all visitors who purchase the plan ... members are encouraged to purchase the insurance program as ... of proper coverage for pre-existing medical conditions. Parents and ... two medical conditions with serious consequences to their health. ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 One ... re-injury, according to research presented today at the American ... Day. The study examined the long term success of ... , “We examined survey data from 242 patients who ... author Justin P. Roe, MBBS, FRACS, from North Sydney ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Genomic medicine ... peritoneal mesothelioma, revealing, for the first time, key information ... here to read the newly posted story on ... the University of British Columbia, the British Columbia Cancer ... mapping to reveal underlying molecular alterations and mutations that ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... Persistent protein expression may explain why tumors return after ... on March 5th in the Journal of ... the most prevalent malignant brain tumor in adults, includes ... of blood vessels to the tumor. Unfortunately, in most ...
... in German . Researchers from the ... cancer cells from chemotherapy -- and they demonstrate which medication ... in the journal Natural Structural and Molecular Biology ... many cancer drugs have already been in use for decades, ...
... JACKSONVILLE, Fla. Researchers have identified a gene that causes ... necks twist involuntarily. The discovery by a team from the ... Tennessee Health Sciences Center sheds light on a movement disorder ... the Annals of Neurology . In ...
... HealthDay Reporter , FRIDAY, March 2 (HealthDay News) -- Driven ... of their own biology, women are more likely than men ... insomnia much more frequently in women, probably at least 50 ... assistant professor of neurology at the University of Texas Southwestern ...
... FRIDAY, March 2 (HealthDay News) -- Preemies face a relatively ... research suggests that the degree to which a child,s health ... child was. Those born between the 32nd and 36th ... issues than those born slightly later in the 37th or ...
... and nongovernmental organizations has published a report proposing a ... in asthma clinical research. Asthma Outcomes in Clinical Research: ... a supplement to the March 2012 issue of the ... from a meeting organized by the National Institutes of ...
Cached Medicine News:Health News:How chemotherapy becomes more effective 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 2Health News:Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder 3Health News:For Sleep Struggles, Women Urged to Alter Routines 2Health News:For Sleep Struggles, Women Urged to Alter Routines 3Health News:For Sleep Struggles, Women Urged to Alter Routines 4Health News:Timing of Preemie Birth May Be Key to Kids' Health Later 2Health News:Standardized outcome measures proposed for asthma clinical research 2
(Date:3/27/2015)... , March 27, 2015 ... by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter ... X-ray)) & Indication (AF, VT, WPW) - Global Forecasts ... is expected to reach around ~$4.73 Billion by 2019 ... period 2014 to 2019. Browse   ...
(Date:3/27/2015)... 2015  Johnson & Johnson (NYSE: JNJ ) will ... Time) on Thursday, April 23, 2015, from the State Theatre ... Investors and other interested parties may access the live audio ... www.jnj.com and clicking on the webcast icon. ... made available a few hours after the live meeting concludes. ...
(Date:3/26/2015)... HOUSTON , March 26, 2015  The ... of a study independently conducted by the Department ... Japan have been published. ... compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant ... colorectal metastasis of the liver. ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Flu Shot Clinics Nationwide, COLUMBIA, Md., Oct. 16 ... flu clinics hosted by Maxim Health Systems.,The company,s Web ... based on user zip codes. "We are in ... too late,to get vaccinated," said Steve Pellito, National Director ...
... Iowa, Oct. 16 Protocol Driven Healthcare,Inc. ... a partnership,with Hallmark Insights to provide fully ... of the ConXus health improvement platform. ... services,for reward points earned by participants completing ...
Cached Medicine Technology:Flu Season Is Here -- Vaccinations Are Still Plentiful 2Flu Season Is Here -- Vaccinations Are Still Plentiful 3PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
... The Medtronic InSync II Marquis ... and ICD therapy. Cardiac resynchronization benefits ... adapt pacing outputs to unique patient ... monitoring functions that help physicians manage ...
... housing. MRI-compatible. Requires a guide sphere ... a standard 1.0 - 1.5 cm burr ... assembly with a white collar. MRI-compatible. ... Sterile; single-use only Guide sphere assembly with ...
... PCL Guides were developed to reproducibly and ... arthroscopic double bundle PCL reconstruction. The guides ... posteromedial femoral tunnel sockets drilled endoscopically from ... placement a guide can be used either ...
... new standard in the field of hammertoe implants ... of medical grade silicone, these durable and lasting ... level of flexibility while maintaining correct toe length ... varying stiffnesses. Lengths are determined by the surgeon ...
Medicine Products: